Author:
Yaghoobi Reza,Omidian Mohammad,Bagherani Nooshin
Abstract
Abstract
Background
Vitiligo is the most prevalent pigmentary disorder which occurs worldwide, with an incidence rate between 0.1-4 percent. It is anticipated that the discovery of biological pathways of vitiligo pathogenesis will provide novel therapeutic and prophylactic targets for future approaches to the treatment and prevention of vitiligo. The purposes of this study were evaluating the efficacy of supplemental zinc on the treatment of vitiligo.
Methods
This randomized clinical trial was conducted for a period of one year. Thirty five patients among 86 participants were eligible to entrance to the study. The patients in two equal randomized groups took topical corticosteroid and combination of oral zinc sulfate-topical corticosteroid.
Results
The mean of responses in the corticosteroid group and the zinc sulfate-corticosteroid combination group were 21.43% and 24.7%, respectively.
Conclusion
Although, the response to corticosteroid plus zinc sulfate was more than corticosteroid, there was no statistically significant difference between them. It appeared that more robust long-term randomized controlled trials on more patients, maybe with higher doses of zinc sulfate, are needed to fully establish the efficacy of oral zinc in management of vitiligo.
Trial Registration
chiCTRTRC10000930
Publisher
Springer Science and Business Media LLC
Reference37 articles.
1. Birlea SA, Fain PR, Spritz RA: A Romanian population isolate with high frequency of vitiligo and associated autoimmune diseases. Arch Dermatol 2008, 144: 310–316. 10.1001/archderm.144.3.310
2. Howitz J, Brodthagen H, Schwartz M, Thomsen K: Prevalence of vitiligo. Arch Dermatol 1977, 113: 47–52. 10.1001/archderm.113.1.47
3. Shameer P, Prasad PVS, Kaviarasan PK: Serum zinc level in vitiligo: a case control study. Indian J Dermatol Venereol Leprol 2005, 71: 206–207. 10.4103/0378-6323.16243
4. Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ: Fitzpatrick's Dermatology in General Medicine. Volume I. 7th edition. Mac Graw Hill; 2007:616–621.
5. Daneshpazhooh M, Mostofizadeh GM, Behjati J, Akhyani M, Mahmoud Robati R: Anti-thyroid peroxidase antibody and vitiligo: a controlled study. BMC Dermatol 2006, 6: 3. 10.1186/1471-5945-6-3
Cited by
36 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献